Carna Biosciences,Inc.
TSE Growth
¥427.00
-2.73%
Delayed · cached 15 min
Price Chart
Price50-day avg200-day avg
How to read this: the line is the closing price over time. The two dashed lines are moving averages — the average price over the last 50 and 200 trading days — which smooth out daily noise to show the broader trend. Price above its moving averages reflects recent strength; below reflects recent weakness. Use the buttons to change the time range. Prices are end-of-day, not live.
✓Strengths
- Current assets comfortably cover current liabilities (current ratio 6.99).
!Watch-points
- Higher leverage: debt-to-equity of 2.98 is above 1.
- Thin interest cover: operating profit covers interest only about -211.2 times.
- Return on equity is on the lower side at -941.4%.
- Return on capital employed is on the lower side at -195.5%.
- The company reported a net loss in the latest period.
- Sales growth has been slow over five years (about -27% a year).
These points are generated automatically from the company’s reported figures to highlight what stands out. They are descriptive observations for educational purposes only — not advice or a recommendation to buy, sell, or hold.
Forensic Checks
Altman Z-ScoreDistress zone
-6.37
In Altman’s study, scores in this range were associated with a higher incidence of financial distress.
Computed without the market-value term.
Piotroski F-ScoreWeak
1 / 4
The F-Score adds one point for each of several year-on-year signs of improving profitability, lower leverage and better efficiency. Higher is generally stronger.
Based on 4 of the 9 signals — the rest need data not available for this stock.
These are well-known academic screening models, shown for educational context only. They describe historical financial patterns and are not predictions, advice, or a recommendation to buy, sell, or hold.
Key Ratios
Market Cap¥90億
Current Price¥ 427.00
High / Low¥ 512.00 / 200.00
Stock P/E-3.76
Book Value¥ 16.16
Dividend Yield0%
ROCE-195.46%
ROE-941.44%
Debt to Equity2.98
Current Ratio6.99
P/B Ratio-22.138117
EPS¥ -113.62
PAT Margin-375.00%
ICR-211.21
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity